Study of EVO756 for Migraine
This study is testing a new medication called EVO756 to see if it can reduce the number of monthly migraine days in adults. Researchers will compare two different doses of EVO756 to a placebo (an inactive substance) over a 12-week treatment period. You might be able to join if you are between 18 and 64 years old, have migraines with or without aura, and have tried other migraine prevention treatments that didn't work. You cannot join if you have trouble telling your migraines apart from other headaches or are using certain medications. The study is looking for 330 participants, but its current recruitment status is unclear.
- Study design
- This interventional study will involve 330 participants who will receive either EVO756 (two different doses) or a placebo daily.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured at the last month of the 12-week treatment period, but further follow-up is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of EVO756 in Adults With Migraine
At a glance
Conditions
Where it's being run
20 sites across 12 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Mean change from baseline in the number of monthly migraine days (MMD)Last month of the 12-week treatment period